Cencora, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Mauch
- Full Time Employees
- 51,000
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- 1 West First Avenue Conshohocken PA United States of America 19428-1800
- IPO Date
- Apr 4, 1995
- CIK
- 0001140859
- Website
- cencora.com
- Similar Companies
- Business
- Cencora, Inc. (NYSE: COR) serves as a leading global pharmaceutical solutions organization that provides end-to-end pharmaceutical distribution, commercialization support, and related services to manufacturers, healthcare providers, pharmacies, hospitals, and health systems worldwide. Founded in 1871 and headquartered in Conshohocken, Pennsylvania, the company operates through U.S. Healthcare Solutions and International Healthcare Solutions segments; it distributes brand-name, specialty brand-name, generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment; offers wholesale and specialty distribution, pharmacy solutions, provider solutions, hospital and health system solutions, logistics and warehousing, drug research and clinical development support, commercialization support, and patient access and adherence programs; and serves acute care hospitals, independent and chain retail pharmacies, mail-order facilities, physicians, clinics, long-term care, assisted living centers, workers' compensation patients, and alternate site facilities across the United States, Canada, and other international markets. In recent developments, Cencora changed its name from AmerisourceBergen Corporation in August 2023; entered a definitive agreement in November 2024 to acquire Retina Consultants of America, a management services organization for retina specialists, for approximately $4.6 billion in cash plus up to $500 million in contingent consideration to expand its specialty capabilities and physician relationships; and announced in November 2025 a $1 billion investment through 2030 to strengthen its U.S. distribution network, including a new 530,000-square-foot national distribution center in Harrison, Ohio by spring 2027, expansions in Fontana, California and Dothan, Alabama with advanced automation and increased refrigerated capacity, and enhanced global cold chain logistics with a new third-party logistics facility planned in Italy in 2026.
Bank of Nova Scotia Boosts Stock Holdings in Cencora, Inc. $COR
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Bet on 5 Top-Ranked Stocks With Rising P/E
Cencora: Specialty Infrastructure Is Rewriting The Distributor Model
Is Cencora Inc (COR) Overvalued After 3.9% Rally? GF Value Says Overvalued
Artisan Mid Cap Fund Q2 2026 Performance Review
Carillon Eagle Mid Cap Growth Fund Q2 2026 Portfolio Review
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell?
Cencora Launches Enhanced Nucleus Solution for Specialty Practices
Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices
Cencora Announces Samantha Hammock as Chief Human Resources Officer
2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now
Cencora's Specialty Supply Chain: Where COR's Growth Is Headed
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue?
Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR